MedTrace Logo

Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

NCT01425814 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2017-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

LAS100977

Dry powder inhalation,Once daily, single dose

DRUG

Reference

Dry powder inhalation (capsule),single dose

DRUG

Placebo

Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose

Sponsors & Collaborators

Principal Investigators

  • Carol Astbury, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01425814 on ClinicalTrials.gov